VivoSense, Inc. Company Profile

Background

Founded in 2010 and headquartered in Newport Coast, California, VivoSense, Inc. specializes in developing and validating digital biomarkers derived from wearable sensor data. The company's mission is to advance healthcare research and clinical trials by providing precise, real-world digital clinical measures that enhance patient-focused drug development and precision medicine. VivoSense's proprietary software enables the creation of novel digital endpoints, facilitating the assessment of treatment efficacy and patient well-being across various therapeutic areas.

Key Strategic Focus

VivoSense focuses on integrating wearable sensor data into clinical trials to develop validated digital clinical outcome assessments (COAs). The company's core objectives include:

• Development of Digital Biomarkers: Creating novel digital biomarkers to objectively assess disease symptoms, treatment side effects, and therapeutic efficacy.

• Enhancement of Clinical Trials: Improving the design and execution of clinical trials by incorporating real-world data from wearable technologies.

• Expansion of Technological Platforms: Refining informatics platforms for data analysis from wearable and connected technologies to deliver validated digital COAs.

VivoSense targets primary markets in pharmaceutical clinical trials, healthcare research, and patient wellness, addressing conditions such as cancer, Alzheimer's disease, and rare diseases.

Financials and Funding

In March 2022, VivoSense secured a $25 million Series A financing round co-led by the Perceptive Xontogeny Venture (PXV) Fund and the Debiopharm Innovation Fund. The capital is intended to accelerate the development of novel digital biomarkers, enhance digital COAs, and expand the company's informatics platform for wearable sensor data analysis.

Technological Platform and Innovation

VivoSense's proprietary VivoSense® software is central to its technological platform, enabling the creation and validation of digital biomarkers from wearable sensor data. The software supports:

• Data Integration: Combining data from various wearable sensors to provide comprehensive physiological monitoring.

• Advanced Analytics: Utilizing machine learning algorithms to interpret complex physiological signals and derive meaningful clinical insights.

• Regulatory Compliance: Ensuring that digital endpoints meet regulatory standards for use in clinical trials.

This platform allows for the rigorous interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations.

Leadership Team

• Colin Bower, Chief Executive Officer: Appointed in August 2023, Colin brings over a decade of experience in healthcare technology, having held roles such as President and CEO of Clintara and Chief Growth Officer at Panalgo.

• Dudley Tabakin, Chief Product Officer and Co-Founder: Transitioned from CEO to Chief Product Officer in 2023, focusing on product development. Dudley has been instrumental in establishing VivoSense's reputation in digital biomarker development.

• Kate Lyden, Chief Science Officer: Leads scientific research initiatives, contributing to the development and validation of digital biomarkers.

• Doug McAllister, Chief Technology Officer: Oversees technological advancements and the integration of wearable sensor data into the company's platforms.

Leadership Changes

In August 2023, Colin Bower joined VivoSense as Chief Executive Officer, succeeding co-founder Dudley Tabakin, who transitioned to the role of Chief Product Officer. This strategic leadership change aims to drive the next phase of the company's development and expansion.

Competitor Profile

Market Insights and Dynamics

The digital health market, particularly in the realm of wearable sensor data integration into clinical trials, is experiencing significant growth. The demand for real-world data to enhance clinical outcomes and patient care is driving innovation and competition in this sector.

Competitor Analysis

Key competitors in the digital biomarker and wearable sensor data analysis space include:

• Koneksa: Specializes in integrating wearable sensor data into clinical trials, focusing on remote patient monitoring and digital biomarker development.

• PhysIQ: Offers continuous biosensor data collection and advanced analytics to monitor patient physiology, aiming to improve clinical trial outcomes and patient care.

These companies, along with VivoSense, are contributing to the evolving landscape of digital health technologies, each bringing unique approaches to integrating wearable sensor data into clinical research.

Strategic Collaborations and Partnerships

VivoSense has established several strategic partnerships to enhance its technological capabilities and market reach:

• ActiGraph: In May 2019, VivoSense partnered with ActiGraph to enhance secure access to regulated sensor data from patients in pharmaceutical clinical trials. This collaboration aims to provide sponsors with secure, analyzed, and contextualized sensor data.

• Cardiac Insight, Inc.: VivoSense partnered with Cardiac Insight to expand the use of wearable cardiac sensors in regulated pharmaceutical clinical trials and healthcare research applications.

• Cambridge Cognition: In June 2023, VivoSense collaborated with Cambridge Cognition to capture measures of cognitive and physical function using digital health tools, indicating a potential avenue for integrating their wearable sensor solutions with cognitive assessment platforms.

Operational Insights

VivoSense's strategic focus on developing validated digital biomarkers and enhancing clinical trials through wearable sensor data positions the company as a leader in the digital health sector. Its proprietary technology, combined with strategic partnerships, provides a competitive advantage in delivering comprehensive and compliant solutions for clinical research.

Strategic Opportunities and Future Directions

Looking ahead, VivoSense aims to:

• Expand Technological Capacity: Invest in further platform development to accommodate a broader range of physiological data types and clinical applications.